The Research Foundation for Microbial Diseases of Osaka University
发明人:
Mekada, Eisuke,Miyamoto, Shingo
申请号：
AU2006260240
公开号：
AU2006260240B2
申请日:
2006.06.20
申请国别(地区):
AU
年份:
2012
代理人:
摘要：
A therapeutic agent for cancer comprising, as an active ingredient, a substancecapable of binding to HB-EGF to thereby inhibit the binding between HB-EGF andan EGF receptor (particularly CRM197), the cancer being selected from the groupconsisting of bladder cancer, colorectal cancer or disseminated peritonealmetastatic cancer from gastric cancer and pancreatic cancer.
